Ligand Pharmaceuticals Incorporated (LGND)
After hours:
| Previous close | 81.34 |
| Open | 81.00 |
| Bid | 79.98 x 100 |
| Ask | 80.50 x 100 |
| Day's range | 78.84 - 81.23 |
| 52-week range | 49.24 - 94.57 |
| Volume | |
| Avg. volume | 144,787 |
| Market cap | 1.438B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 14.96 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 July 2010 |
| 1y target est | N/A |
- Business Wire
Ligand to Participate in Upcoming Investor Conferences
JUPITER, Fla., May 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences:
- Business Wire
Ligand Reports First Quarter 2024 Financial Results
JUPITER, Fla., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions.
- Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
JUPITER, Fla. and LEXINGTON, Mass., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with met
